Monopar Therapeutics — Director's Dealing 2021

Jan 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2021-01-26

Reporting Person: Mazar Andrew Paul (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-26	Stock Options	$6.81	A	36077	Acquired	2031-01-25	Common Stock (36077)	Direct
2021-01-26	Restricted Stock Units	$0	A	25697	Acquired		Common Stock (25697)	Direct

Footnotes

F1: Options vest 6/48ths on June 30, 2021 and 1/48th monthly on the last day of each month thereafter.

F2: RSUs vest 6/48ths on June 30, 2021 and 3/48ths each quarter-end thereafter (September 30, 2021, December 31, 2021, March 31, 2022, June 30, 2022, September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024)